Workflow
中国抗体-B(03681)与中山大学香港高等研究院订立全面战略合作协议
SINOMAB BIOSINOMAB BIO(HK:03681) 智通财经网·2025-08-12 10:28

Core Viewpoint - China Antibody-B (03681) has entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute (SYSU-IAS) to conduct joint research and development in the biomedical field over a three-year period [1] Group 1: Strategic Cooperation - The cooperation agreement aims to leverage the combined strengths of the company and SYSU-IAS to accelerate the development of innovative drugs and facilitate the translation of research results into clinical applications globally [1] - The collaboration will adopt a project-driven model, focusing on resource sharing and efficient communication as its core framework [1] - This strategic partnership is expected to provide the company direct access to SYSU-IAS's comprehensive laboratory facilities, animal supply resources (especially non-primate animals), and valuable data assets, which are critical for advancing drug research and ensuring sustainable development [1] Group 2: Long-term Growth and Sustainability - The board of directors believes that this strategic cooperation establishes a mutually beneficial framework that will help drive growth and ensure long-term sustainability [1] - The collaboration aligns with the company's strategy to advance its innovative drug portfolio [1]